<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03804879</url>
  </required_header>
  <id_info>
    <org_study_id>CLMB763X2202</org_study_id>
    <secondary_id>2018-002491-40</secondary_id>
    <nct_id>NCT03804879</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Randomized Patient-and-physician Blinded, Placebo-controlled, 24-week Study to Assess the Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore&#xD;
      has the potential to improve the management of diabetic kidney disease when added to the&#xD;
      standard of care (angiotensin converting enzyme inhibitor or angiotensin receptor blocker).&#xD;
      This non-confirmatory Phase 2 study is designed to determine the safety, tolerability,&#xD;
      efficacy, pharmacokinetics and pharmacodynamics of nidufexor in combination with angiotensin&#xD;
      converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at a dose level that&#xD;
      is standard of care as judged by the study doctor in patients with type 2 diabetes and&#xD;
      nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">May 3, 2021</completion_date>
  <primary_completion_date type="Actual">May 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urinary albumin to creatinine ratio</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor to placebo on albuminuria in patients with diabetic nephropathy already receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in 24 hour urinary albumin</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor to placebo on albuminuria in patients with diabetic nephropathy already receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events and study drug related adverse events</measure>
    <time_frame>168 days</time_frame>
    <description>Adverse event profile and safety endpoints of nidufexor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically notable deviations in laboratory test results</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on laboratory measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically notable deviations in vital signs</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically notable deviations in ECG parameters</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on ECG parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on renal filtration function utilizing Estimated glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of nidufexor at day 1 and at steady state in patients with type 2 diabetes and nephropathy</measure>
    <time_frame>168 days</time_frame>
    <description>To assess the Cmax of nidufexor at day 1 and at steady state in patients with type 2 diabetes and nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of nidufexor at day 1 and at steady state in patients with type 2 diabetes and nephropathy</measure>
    <time_frame>168 days</time_frame>
    <description>To assess the Tmax of nidufexor at day 1 and at steady state in patients with type 2 diabetes and nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of nidufexor at day 1 and at steady state in patients with type 2 diabetes and nephropathy</measure>
    <time_frame>168 days</time_frame>
    <description>To assess the AUC of nidufexor on day 1 and at steady state in patients with type 2 diabetes and nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Free water clearance</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on renal tubular function utilizing Free water clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Fasting lipid profile, including lipoprotein (a) [Lp(a)]</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on lipids utilizing Fasting lipid profile, including lipoprotein (a) [Lp(a)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on anthropometric assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body mass index (BMI)</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on anthropometric assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist-to-hip ratio</measure>
    <time_frame>168 days</time_frame>
    <description>Effect of nidufexor on anthropometric assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>LMB763</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LMB763 capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMB763</intervention_name>
    <description>LMB763 capsule</description>
    <arm_group_label>LMB763</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female patients, 18-75 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Diagnosis of Type 2 diabetes mellitus, with diagnosis made at least 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Diabetic nephropathy as evidenced by Urine albumin-Cr ratio (UACR) â‰¥300 mg/g Cr at&#xD;
             screening while receiving a dose of angiotensin converting enzyme inhibitor or&#xD;
             angiotensin receptor blocker that is the standard of care as judged by the study&#xD;
             doctor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes mellitus&#xD;
&#xD;
          -  Severe renal impairment manifesting as serum creatinine eGFR &lt; 30 mL/min/1.73 m^2 at&#xD;
             screening&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential, unless they are using basic methods of contraception&#xD;
             during dosing of study treatment&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus at screening&#xD;
&#xD;
          -  History or current diagnosis of ECG abnormalities prior to first study dose&#xD;
&#xD;
          -  History of kidney disease other than diabetic nephropathy at screening&#xD;
&#xD;
          -  Uncontrolled hypertension at screening&#xD;
&#xD;
          -  Use of prohibited medications, including but not limited to GLP-1 agonists and SGLT2&#xD;
             inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1407</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhine Westphalia</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elsterwerda</city>
        <zip>04910</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saida</city>
        <zip>652</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talas / Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

